Leroy F
Acta Genet Med Gemellol (Roma). 1979;28(4):303-9. doi: 10.1017/s0001566000008837.
A continuous series of 483 twin deliveries was studied. In 30% of cases, intravenous oxytocic treatment was given for labour induction or to accelerate the first stage. In 13% of twin deliveries this treatment was applied only after the first twin's birth. In the group perfused during cervix dilatation, foetal mortality rate was significantly lower than in the nontreated group. In order to understand the reason(s) for this difference, the following factors were studied in relation to oxytocic treatment: parity, obstetrical complications, second stage duration, abnormal presentations, obstetrical maneuvers, and birth weight. Contrasting with mortality data, Apgar scores of first twins were significantly lower in the oxytocin-treated group. In summary, several variables indirectly linked to oxytocic treatment could have favoured or hampered foetal outcome in the treated group. Therefore, it is difficult to ascertain if the use of oxytocics is helpful in twin pregnancy management. In the majority of cases, however, it may at least be considered harmless.
对连续483例双胎分娩进行了研究。在30%的病例中，为引产或加速第一产程给予了静脉缩宫素治疗。在13%的双胎分娩中，这种治疗仅在第一个胎儿出生后应用。在宫颈扩张期接受灌注的组中，胎儿死亡率显著低于未治疗组。为了理解这种差异的原因，研究了以下与缩宫素治疗相关的因素：产次、产科并发症、第二产程持续时间、胎位异常、产科操作和出生体重。与死亡率数据相反，缩宫素治疗组中第一个胎儿的阿氏评分显著较低。总之，与缩宫素治疗间接相关的几个变量可能对治疗组的胎儿结局有利或有阻碍。因此，很难确定缩宫素的使用对双胎妊娠管理是否有帮助。然而，在大多数情况下，至少可以认为它是无害的。
